Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:HALO
CUSIP40637H10
Phone858-794-8889
Debt
Debt-to-Equity Ratio0.39
Current Ratio4.06
Quick Ratio4.03
Price-To-Earnings
Trailing P/E Ratio42.60
Forward P/E Ratio-20.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$316.61 million
Price / Sales8.74
Cash Flow$0.4626 per share
Price / Cash41.53
Book Value$1.46 per share
Price / Book13.16
Profitability
EPS (Most Recent Fiscal Year)$0.45
Net Income$62.97 million
Net Margins21.52%
Return on Equity45.31%
Return on Assets15.93%
Miscellaneous
Employees255
Outstanding Shares143,970,000
Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions
What is Halozyme Therapeutics' stock symbol?
Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."
How were Halozyme Therapeutics' earnings last quarter?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.03. The biopharmaceutical company earned $30.90 million during the quarter, compared to the consensus estimate of $31.84 million. Halozyme Therapeutics had a net margin of 21.52% and a return on equity of 45.31%. The firm's quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.26) EPS. View Halozyme Therapeutics' Earnings History.
When is Halozyme Therapeutics' next earnings date?
What price target have analysts set for HALO?
8 analysts have issued 1 year price targets for Halozyme Therapeutics' stock. Their predictions range from $7.00 to $29.00. On average, they expect Halozyme Therapeutics' share price to reach $19.75 in the next year. View Analyst Ratings for Halozyme Therapeutics.
Who are some of Halozyme Therapeutics' key competitors?
Some companies that are related to Halozyme Therapeutics include Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), argenx (ARGX), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA), Repligen (RGEN) and Editas Medicine (EDIT).
Who are Halozyme Therapeutics' key executives?
Halozyme Therapeutics' management team includes the folowing people:
- Dr. Helen I. Torley, Pres, CEO & Director (Age 55)
- Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 50)
- Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 61)
- Mr. Mark J. Gergen, Former Chief Operating Officer (Age 55)
- Dr. Michael J. LaBarre Ph.D., Chief Scientific Officer and VP (Age 54)
Has Halozyme Therapeutics been receiving favorable news coverage?
News stories about HALO stock have trended somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Halozyme Therapeutics earned a coverage optimism score of 0.12 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.12 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Halozyme Therapeutics' major shareholders?
Halozyme Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.06%), Iridian Asset Management LLC CT (5.70%), JPMorgan Chase & Co. (2.17%), First Eagle Investment Management LLC (2.09%), Artisan Partners Limited Partnership (1.18%) and Northern Trust Corp (1.15%). View Institutional Ownership Trends for Halozyme Therapeutics.
Which major investors are selling Halozyme Therapeutics stock?
HALO stock was sold by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, Iridian Asset Management LLC CT, BlackRock Inc., Rubric Capital Management LP, Russell Investments Group Ltd., American Century Companies Inc., Millennium Management LLC and A.R.T. Advisors LLC. View Insider Buying and Selling for Halozyme Therapeutics.
Which major investors are buying Halozyme Therapeutics stock?
HALO stock was purchased by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Dimensional Fund Advisors LP, Schwab Charles Investment Management Inc., Alambic Investment Management L.P., Victory Capital Management Inc., GSA Capital Partners LLP, UBS Group AG and Federated Investors Inc. PA. View Insider Buying and Selling for Halozyme Therapeutics.
How do I buy shares of Halozyme Therapeutics?
Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Halozyme Therapeutics' stock price today?
One share of HALO stock can currently be purchased for approximately $19.21.
How big of a company is Halozyme Therapeutics?
Halozyme Therapeutics has a market capitalization of $2.72 billion and generates $316.61 million in revenue each year. The biopharmaceutical company earns $62.97 million in net income (profit) each year or $0.45 on an earnings per share basis. Halozyme Therapeutics employs 255 workers across the globe.
How can I contact Halozyme Therapeutics?
Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]
MarketBeat Community Rating for Halozyme Therapeutics (HALO)
MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days.
